Deculin 15
Indication
Combination therapy
Deculin is indicated as a combination therapy with sulfonylurea or metformin in patients with type-2 diabetes mellitus who are inadequately controlled on sulfonylurea and metformin monotherapy.
Composition
Pioglitazone 15 mg
Package
Dosage Forms
ATC Classification
Warning
Dosage
0 to 18 Years Old
No data are available of pioglitazone in children and adolescents under 18 years of age, therefore pioglitazone should not be used for that patients.
18 to 65 Years Old
Combination with metformin:
15-30 mg once daily. The current metformin dose can be continued upon initiation of pioglitazone therapy.
Combination with sulfonylurea:
15-30 mg once daily. The current sulfonylurea dose can be continued upon initiation of pioglitazone therapy. If hypoglycemia occurs, the dose of the sulfonylurea should be decreased. If hypoglycemia occurs, the dose of the sulfonylurea should be decreased.
65 Years Old and Above
No dose adjustment is necessary for elderly patients.
Administration
Should be taken once daily with or without food.
Patients with Impaired Renal Function
No dose adjustment is necessary in patients with renal failure (creatinine clearance >4 ml/minute).
Patients with Impaired Hepatic Function
Pioglitazone should not be used in patients with hepatic impairment.